Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Fineline Cube May 7, 2026
Company Deals

Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs

Fineline Cube Mar 3, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in...

Company

AI in Healthcare: Accelerating Applications in Diagnostics and Multi-omics Analysis

Fineline Cube Mar 2, 2025

The breakthrough technology of DeepSeek has significantly accelerated the application of AI in the medical...

Company

Biointron Biologics Files for Public Offering, Aims for BSE Listing

Fineline Cube Mar 2, 2025

On February 11, Biointron Biologics released its tutoring filing report for the public offering of...

Company

Biocytogen Completes DeepSeek Localization, Integrates with “Thousand Mice, Ten Thousand Antibodies” Plan

Fineline Cube Mar 1, 2025

On February 28, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has completed...

Company

BeiGene’s Q4 and 2024 Financials Highlight Significant Growth and Product Success

Fineline Cube Feb 28, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released financial results and corporate updates from...

Company

Zai Lab Q2 and Full-Year 2024 Report Shows Sales Growth and Loss Reduction

Fineline Cube Feb 28, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 and full-year 2024...

Company

Viatris Q4 and Full-Year Results Show Greater China Growth

Fineline Cube Feb 28, 2025

US generics giant Viatris (NASDAQ: VTRS) released its Q4 and full-year 2024 financial results. In...

Company Deals

SciClone Pharmaceuticals Licenses Eisai’s Tasurgratinib for China

Fineline Cube Feb 28, 2025

China-based SciClone Pharmaceuticals Inc. announced a licensing agreement with Eisai Co., Ltd (TYO: 4523), securing...

Company Drug

Fosun Pharmaceutical’s XS-03 Gets NMPA Green Light for CRC Study

Fineline Cube Feb 28, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...

Company Deals

Sino Biopharmaceutical and Sciwind Biosciences Partner on CPX102 Development

Fineline Cube Feb 28, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced a strategic partnership with compatriot firm Sciwind Biosciences...

Company Drug

Bayer’s BlueRock Therapeutics Gets Fast Track for OpCT-001 Therapy

Fineline Cube Feb 28, 2025

German pharmaceutical giant Bayer (ETR: BAYN) and its wholly owned subsidiary BlueRock Therapeutics LP announced...

Company Drug

Chipscreen Biosciences’ CS12088 Gets NMPA Clearance for Hepatitis B Study

Fineline Cube Feb 28, 2025

China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that the National Medical Products Administration...

Company Drug

Hengrui Pharmaceuticals Gets NMPA Green Light for SHR-A2009 Study

Fineline Cube Feb 28, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that the National Medical Products Administration...

Company

GE Healthcare’s China CEO Yihao Zhang to Retire, Will Song Named Successor

Fineline Cube Feb 28, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the...

Company Medical Device

Zhongsheng Pharmaceutical’s RAY1225 Gets Green Light for Phase III Study

Fineline Cube Feb 28, 2025

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval in...

Company Drug

Akeso Inc. Completes Patient Enrollment for AK138D1 Phase I Study

Fineline Cube Feb 28, 2025

China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the Phase...

Company Drug

CARsgen Therapeutics Administers KJ-C2219 in SLE Patient in IIT

Fineline Cube Feb 28, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at...

Company Drug

Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer

Fineline Cube Feb 28, 2025

China-based Adagene Inc. (NASDAQ: ADAG) announced the initiation of an Investigator-Initiated (IIT) Phase II trial...

Company Drug

Shanghai Moyang Biotech’s Aphranel CC Needle Wins NMPA Approval

Fineline Cube Feb 28, 2025

China-based Shanghai Moyang Biotechnology Co., Ltd, an innovation-focused company in nanomedical biomaterials and Class III...

Company Drug

Huadong Medicine’s ADC HDM2005 Granted FDA Orphan Drug Designation for MCL

Fineline Cube Feb 28, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its antibody-drug conjugate (ADC) HDM2005 has...

Posts pagination

1 … 199 200 201 … 661

Recent updates

  • Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio
  • Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients
  • Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion
  • Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 – China’s First Broad-Spectrum β-Lactamase Inhibitor for Drug-Resistant Pneumonia
  • Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Company Drug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Company Drug

Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 – China’s First Broad-Spectrum β-Lactamase Inhibitor for Drug-Resistant Pneumonia

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.